Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants
Authors:
- 1 June 2012
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (6) , 819-827
Abstract
Aclidinium bromide is a long‐acting muscarinic antagonist in development for chronic obstructive pulmonary disease treatment. This 2‐part, phase I study evaluated the safety and tolerability of single ascending intravenous (IV) doses of aclidinium to determine its maximum tolerated dose (MTD; part I) and its absolute bioavailability (part II). Healthy male participants (N = 24) were randomized (1:1) in each part: 3‐period crossover, placebo‐controlled, single‐ascending, alternating IV doses of aclidinium (25–400 μg) in part I and 2‐period crossover, single‐alternating IV and inhaled doses of aclidinium (200 μg) in part II. A ≥7‐day washout separated treatment periods. Pharmacokinetic data were collected in both parts. Following IV or inhaled aclidinium, time to reach maximum plasma concentration following drug administration (tmax) was 5 to 7 minutes for all doses. After maximum plasma drug concentration (Cmax), aclidinium was rapidly cleared from plasma. Aclidinium absolute bioavailability was <5% following a single inhaled 200‐μg dose. Urinary excretion of unchanged aclidinium was very low, with a greater amount of inactive metabolites excreted compared with aclidinium, all of which were recovered within 12 hours postdose. The MTD following IV administration was not reached; all single IV (25–400 μg) and inhaled doses (200 μg) were well tolerated. In conclusion, the low and short‐lived bioavailability of aclidinium and the low incidence of systemic side effects contribute to its positive safety and tolerability profile.Keywords
This publication has 16 references indexed in Scilit:
- Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trialClinical Therapeutics, 2010
- Identification of the Human Enzymes Responsible for the Enzymatic Hydrolysis of Aclidinium BromideDrug Metabolism and Disposition, 2010
- Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: In vitro plasma inactivation and pharmacological activity of its main metabolitesEuropean Journal of Pharmaceutical Sciences, 2010
- Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological ProfileThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Tiotropium HandiHaler® in the treatment of COPD: A safety reviewInternational Journal of Chronic Obstructive Pulmonary Disease, 2009
- Discovery of Novel Quaternary Ammonium Derivatives of (3R)-Quinuclidinol Esters as Potent and Long-Acting Muscarinic Antagonists with Potential for Minimal Systemic Exposure after Inhaled Administration: Identification of (3R)-3-{[Hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane Bromide (Aclidinium Bromide)Journal of Medicinal Chemistry, 2009
- Global burden of COPD: risk factors, prevalence, and future trendsThe Lancet, 2007
- Projections of Global Mortality and Burden of Disease from 2002 to 2030PLOS Medicine, 2006
- Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paperEuropean Respiratory Journal, 2004
- Pharmacokinetics of Intravenous, Single‐Dose Tiotropium in Subjects with Different Degrees of Renal ImpairmentThe Journal of Clinical Pharmacology, 2004